Abstract: Disclosed is a process for the production of chondroitin sulphate, wherein N-acetyl-galactosamine residues sulphated at the 4- or 6-positions are present on the same polysaccharide chain.
Type:
Application
Filed:
November 11, 2011
Publication date:
August 29, 2013
Applicant:
ALTERGON S.A.
Inventors:
Emiliano Bedini, Mario De Rosa, Cristina De Castro, Annalida Di Nola, Michelangelo Parrilli, Odile Francesca Restaino, Chiara Schiraldi
Abstract: Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.
Type:
Application
Filed:
September 9, 2011
Publication date:
June 27, 2013
Applicant:
Altergon S.A.
Inventors:
Mario De Rosa, Antonella D'agostino, Annalisa La Gatta, Chiara Schiraldi
Abstract: The present invention concerns an aqueous pharmaceutical composition for bladder instillation, cystitis therapy, or interstitial cystitis therapy, the aqueous composition containing water, hyaluronic acid or a salt thereof and/or chondroitin sulphate or a salt thereof, and a pharmaceutically acceptable bivalent metal ion, wherein the bivalent metal ion is chosen from calcium and magnesium, and wherein the bivalent ion lowers the viscosity of the composition.
Type:
Grant
Filed:
May 25, 2007
Date of Patent:
August 28, 2012
Assignee:
Altergon S.A.
Inventors:
Giorgio Zoppetti, Nadia Puppini, Marco Pizzutti
Abstract: The present invention relates to a process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, its components including as active principle a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic base chosen from hydroxyethylpyrrolidine or hydroxyethylpiperidine characterized in that said active principle is added to a mixture of one or more of said components, in the form of a solution in water and propylene glycol in a ratio of about 1:1 parts by weight.
Abstract: The present disclosure relates to a container for pharmaceutical use for the quantitative release of a single-dose for oral administration of the T3 and T4 thyroid hormones in solution, characterized by the fact of being formed with a plastic material having a Young's modulus between 10 and 80 MPa.
Abstract: The present invention provides for pharmaceutical formulations based on thyroid hormones enabling a safe and stable oral administration in the framework of the strict therapeutic index prescribed in case of thyroid disorders.
Type:
Grant
Filed:
July 2, 2002
Date of Patent:
May 25, 2010
Assignee:
Altergon S.A.
Inventors:
Alberto Garavani, Maurizio Marchiorri, Alessandro Di Martino, Angel Mateo Echanagorria
Abstract: The present invention provides pharmaceutical formulation for thyroid hormones which allow safe and stable administration by mouth within the ambit of the narrow therapeutic index prescribed in the case of thyroid dysfunctions, as well as procedures for obtaining them.
Type:
Grant
Filed:
December 23, 2003
Date of Patent:
April 6, 2010
Assignee:
Altergon S.A.
Inventors:
Alessandro Di Martino, Angel Mateo, Alberto Garavani, Maurizio Marchiorri
Abstract: The present invention concerns new compositions comprising glycosaminoglycans, intended for use in interstitial cystitis therapy, and characterized by a controlled viscosity.
Type:
Application
Filed:
May 25, 2007
Publication date:
July 16, 2009
Applicant:
Altergon S.A.
Inventors:
Giorgio Zoppetti, Nadia Puppini, Marco Pizzutti
Abstract: Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising:
a substrate layer;
an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid;
a protective film which can be removed at the moment of use.
Abstract: Thin adhesive plaster having a thickness lower than 500 &mgr;m for the treatment of psoriasis, dermatitis and dermatosis, comprising:
a) a support comprising an outer layer in plastic film and an inner layer in woven or non-woven fabric having approximately the same size as the plastic film,
b) an adhesive layer placed on the support inner layer having approximately the same size as the support comprising an adhesive matrix in the form of hydrogel, betamethasone or a pharmaceutically acceptable salt thereof and optionally hyaluronic acid or a pharmaceutically acceptable salt thereof,
c) a protective plastic film contacted with the adhesive layer and removable immediately prior to use.
Abstract: An external anti-inflammatory and analgesic plaster preparation includes as an active ingredient a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic having the general formula (I): ##STR1## wherein X is a group of the formula --(CH.sub.2)m-- in which m is an integer of 0 or 1 and n is an integer of 2 and a pH value of the preparation is adjusted to a range of 7.3 to 9.0.
Abstract: The salts, in the crystalline form, of ibuprofen and naproxen with N-(2-hydroxyethyl) pyrrolidine are prepared by dissolving ibuprofen and naproxen respectively in a suitable organic solvent, by adding N-(2-hydroxyethyl) pyrrolidine, by letting the compounds react, by removing the solvent and by crystallizing the obtained salt from a solution in an apolar and aprotic solvent.Said salts have a high solubility in water and are used for preparing pharmaceutic compositions for oral and other administrations.
Type:
Grant
Filed:
June 23, 1992
Date of Patent:
April 27, 1993
Assignee:
Altergon S.A.
Inventors:
Elisabetta Donati, Irina Rapaport, Paolo Lualdi
Abstract: A month-soluble pharmaceutical composition comprising acetylcysteine, alkaline, bicarbonates, carbohydrates and fruit flavoring, produced in the form of tablets for treating affections of the oral cavity.
Abstract: The salt of diclofenac with a cyclic organic base is prepared by dissolving diclofenac in a suitable organic solvent, adding said cyclic organic base, reacting the two components together, removing the solvent and crystallizing the product obtained.Said salt is water soluble to an extent from 20% w/v to an extent exceeding 50% w/v, and is used to prepared pharmaceutical compositions preferably in granular form for use by dissolving in water for oral administration.